Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Armata Pharmaceuticals, Inc. (ARMP) reported a Q3 loss of $0.15 per share, which was better than the Zacks Consensus Estimate of a $0.28 loss. This is an improvement from the $0.31 loss per share reported a year ago.
November 13, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Armata Pharmaceuticals reported a Q3 loss of $0.15 per share, better than the expected $0.28 loss, and an improvement from last year's $0.31 loss.
The better-than-expected earnings report, with a smaller loss than anticipated, is likely to positively impact ARMP's stock price in the short term. The improvement from last year's loss also indicates progress, which could boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100